MAIA Biotechnology Inc (MAIA)
3.28
+0.13
(+4.13%)
USD |
NYAM |
May 03, 16:00
3.05
-0.23
(-7.01%)
After-Hours: 06:13
MAIA Biotechnology Research and Development Expense (Quarterly): 3.717M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.717M |
| September 30, 2023 | 2.600M |
| June 30, 2023 | 2.599M |
| March 31, 2023 | 2.145M |
| December 31, 2022 | 2.393M |
| September 30, 2022 | 2.343M |
| Date | Value |
|---|---|
| June 30, 2022 | 2.120M |
| March 31, 2022 | 2.048M |
| December 31, 2021 | 1.465M |
| September 30, 2021 | 1.082M |
| June 30, 2021 | 0.644M |
| March 31, 2021 | 0.2628M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.2628M
Minimum
Mar 2021
3.717M
Maximum
Dec 2023
1.952M
Average
2.132M
Median
Research and Development Expense (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | 3.518M |
| Avid Bioservices Inc | -- |
| Oragenics Inc | 11.04M |
| NeuBase Therapeutics Inc | 0.3876M |
| Viking Therapeutics Inc | 24.10M |